Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Aethlon Medical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Aethlon Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
Aethlon Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
Aethlon Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Aethlon Medical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Timothy C. Rodell, Jr., M.D., FCCP has been Interim Chief Executive Officer at Aethlon Medical, Inc. since December 10, 2018 and has been its Director since December 2018. Dr. Rodell is a Managing Partner of MTR, Inc. Dr. Rodell is the Founder of Barofold, Inc. He served as the President and Chief Executive Officer of Globeimmune Inc. from June 2005 and April 2003 to November 2016. He served as Chief Technology Officer of Oxis International, Inc. from 2000 to October 2000. He served as President of OXIS Therapeutics, Inc. from March 1998 to October 2000 and served as Chief Operating Officer of OXIS from March 1, 1996 to March 18, 1998. From 1999 to 2002, Dr. Rodell served as the President, Chief Executive Officer and Director at Endo Pharmaceuticals Colorado LLC (formerly RxKinetix, Inc). in Louisville, Colorado. Prior to joining OXIS, Dr. Rodell served as Executive Vice President for Operations and Product Development of Cortech, Inc., from 1985 to 1995, where he led all development of three clinical programs and co-led its successful IPO. He is Director of Globeimmune Inc. since April 2003. He served as a Director of Oxis International, Inc. since 2000. He is Board -certified in Internal Medicine and Pulmonary Medicine. He practiced and taught emergency medicine, internal medicine and pulmonary and critical care medicine at University of Colorado Health Sciences Center and Denver Health (formerly, Denver General Hospital). Dr. Rodell also served as a post-doctoral research fellow at Webb-Waring Lung Institute in Denver, Colorado. He is a Fellow of the American College of Chest Physicians. Dr. Rodell received his M.D. from University of North Carolina School of Medicine in 1980.
Insufficient data for Timothy to compare compensation growth.
Insufficient data for Timothy to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Aethlon Medical management team is about average.
CFO, Senior VP of Finance & Secretary
Interim CEO & Director
Head of Clinical Studies
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Aethlon Medical board of directors is about average.
Board of Directors
Chairman & Member of extracorporeal Therapy Advisory Board
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.